HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duran-Sandoval, D. Articles by Staels, B. Search for Related Content PubMed PubMed Citation Articles by Duran-Sandoval, D. Articles by Staels, B. Social Bookmarking                What's this?

Glucose Regulates the Expression of the Farnesoid X Receptor in Liver

¹ Atherosclerosis Department, Unité de Recherche 545 Institute National de la Santé et de la Recherche Médicale (INSERM), Pasteur Institute of Lille, and the Faculty of Pharmacy, Lille2 University, Lille, France
² Genfit S.A., Loos, France
³ Center for Liver, Digestive and Metabolic Diseases, Laboratory of Pediatrics, University Hospital, Groningen, the Netherlands

An increased prevalence of hypertriglyceridemia and gallbladder disease occurs in patients with diabetes or insulin resistance. Hypertriglyceridemia is positively associated to gall bladder disease risk. The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor that plays a key role in bile acid and triglyceride homeostasis. The mechanisms controlling FXR gene expression are poorly understood. This study evaluated whether FXR gene expression is regulated by alterations in glucose homeostasis. FXR expression was decreased in livers of streptozotocin-induced diabetic rats and normalized upon insulin supplementation. Concomitantly with diabetes progression, FXR expression also decreased in aging diabetic Zucker rats. In primary rat hepatocytes, D-glucose increased FXR mRNA in a dose- and time-dependent manner, whereas insulin counteracted this effect. Addition of xylitol, a precursor of xylulose-5-phosphate, to primary rat hepatocytes increased FXR expression to a comparable level as D-glucose. Finally, expression of the FXR target genes, SHP and apolipoprotein C-III, were additively regulated by D-glucose and FXR ligands. This study demonstrates that FXR is decreased in animal models of diabetes. In addition, FXR is regulated by glucose likely via the pentose phosphate pathway. Dysregulation of FXR expression may contribute to alterations in lipid and bile acid metabolism in patients with diabetes or insulin resistance.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Jiang, X. X. Wang, P. Scherzer, P. Wilson, J. Tallman, H. Takahashi, J. Li, M. Iwahashi, E. Sutherland, L. Arend, et al. Farnesoid X Receptor Modulates Renal Lipid Metabolism, Fibrosis, and Diabetic Nephropathy Diabetes, October 1, 2007; 56(10): 2485 - 2493. [Abstract] [Full Text] [PDF]

				B. Cariou, K. van Harmelen, D. Duran-Sandoval, T. H. van Dijk, A. Grefhorst, M. Abdelkarim, S. Caron, G. Torpier, J.-C. Fruchart, F. J Gonzalez, et al. The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice J. Biol. Chem., April 21, 2006; 281(16): 11039 - 11049. [Abstract] [Full Text] [PDF]

				S. Bilz, V. Samuel, K. Morino, D. Savage, C. S. Choi, and G. I. Shulman Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E716 - E722. [Abstract] [Full Text] [PDF]

				Y. Zhang, F. Y. Lee, G. Barrera, H. Lee, C. Vales, F. J. Gonzalez, T. M. Willson, and P. A. Edwards Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice PNAS, January 24, 2006; 103(4): 1006 - 1011. [Abstract] [Full Text] [PDF]

				E. A. Hanniman, G. Lambert, T. C. McCarthy, and C. J. Sinal Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice J. Lipid Res., December 1, 2005; 46(12): 2595 - 2604. [Abstract] [Full Text] [PDF]

				T. Claudel, B. Staels, and F. Kuipers The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2020 - 2030. [Abstract] [Full Text] [PDF]

				D. Duran-Sandoval, B. Cariou, F. Percevault, N. Hennuyer, A. Grefhorst, T. H. van Dijk, F. J. Gonzalez, J.-C. Fruchart, F. Kuipers, and B. Staels The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition J. Biol. Chem., August 19, 2005; 280(33): 29971 - 29979. [Abstract] [Full Text] [PDF]

				B. Cariou, D. Duran-Sandoval, F. Kuipers, and B. Staels Farnesoid X Receptor: A New Player in Glucose Metabolism? Endocrinology, March 1, 2005; 146(3): 981 - 983. [Full Text] [PDF]

				K. R. Stayrook, K. S. Bramlett, R. S. Savkur, J. Ficorilli, T. Cook, M. E. Christe, L. F. Michael, and T. P. Burris Regulation of Carbohydrate Metabolism by the Farnesoid X Receptor Endocrinology, March 1, 2005; 146(3): 984 - 991. [Abstract] [Full Text] [PDF]